Profile data is unavailable for this security.
About the company
Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.
- Revenue in JPY (TTM)150.19bn
- Net income in JPY14.65bn
- Incorporated1944
- Employees2.76k
- LocationHisamitsu Pharmaceutical Co Inc30F, Marunouchi Bldg., 2-4-1, MarunouchiCHIYODA-KU 100-6221JapanJPN
- Phone+81 352931700
- Fax+81 352931750
- Websitehttps://www.hisamitsu.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd. | 27.95bn | 5.11bn | 346.51bn | 1.65k | 67.75 | 13.65 | 55.14 | 12.40 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Wockhardt Ltd | 53.93bn | -5.27bn | 349.04bn | 2.39k | -- | 5.31 | -- | 6.47 | -19.85 | -19.85 | 201.29 | 221.32 | 0.393 | 1.87 | 4.19 | 12,318,300.00 | -3.93 | -4.56 | -6.33 | -8.29 | 59.10 | 55.26 | -10.00 | -12.70 | 0.5677 | 0.247 | 0.3869 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Lotus Pharmaceutical Co Ltd | 83.51bn | 20.57bn | 360.01bn | 1.10k | 17.34 | 3.74 | 13.52 | 4.31 | 16.47 | 16.47 | 66.89 | 76.24 | 0.5014 | 1.94 | 2.58 | -- | 12.35 | 9.17 | 15.04 | 11.36 | 56.39 | 49.32 | 24.63 | 15.99 | 1.89 | -- | 0.3809 | 26.77 | 15.89 | 21.41 | 35.91 | 110.44 | 52.35 | -- |
| Shanghai Shyndec Pharmaceutical Co Ltd | 245.58bn | 23.11bn | 363.11bn | 11.61k | 15.71 | 1.30 | -- | 1.48 | 0.8071 | 0.8071 | 8.58 | 9.75 | 0.588 | 3.11 | 7.16 | 990,814.20 | 6.99 | 4.85 | 10.16 | 8.17 | 37.73 | 43.00 | 11.88 | 7.03 | 2.03 | -- | 0.1012 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| Hisamitsu Pharmaceutical Co Inc | 150.19bn | 14.65bn | 364.85bn | 2.76k | 21.95 | 1.15 | 17.50 | 2.43 | 195.20 | 195.20 | 1,996.17 | 3,730.09 | 0.4323 | 3.01 | 3.22 | 54,434,580.00 | 4.36 | 4.22 | 5.25 | 4.82 | 56.42 | 58.62 | 10.10 | 10.03 | 3.14 | -- | 0.004 | 53.05 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
| The United Laboratories Intl. Hldgs Ltd. | 298.80bn | 62.03bn | 366.56bn | 15.00k | 5.91 | 1.27 | 4.94 | 1.23 | 1.72 | 1.72 | 8.28 | 8.00 | 0.6578 | 3.30 | 5.67 | 1,003,237.00 | 13.65 | 7.89 | 20.72 | 12.64 | 46.15 | 44.17 | 20.75 | 12.73 | 1.72 | -- | 0.1532 | 28.99 | 21.22 | 12.84 | 70.85 | 31.66 | 24.19 | 46.04 |
| Tonghua Dongbao Pharmaceutical Co Ltd | 51.92bn | 7.29bn | 367.71bn | 3.20k | 56.14 | 2.68 | -- | 7.08 | 0.1548 | 0.1548 | 1.25 | 3.24 | 0.3394 | 0.7426 | 3.70 | 760,839.10 | 4.76 | 18.68 | 5.04 | 19.68 | 77.31 | 78.73 | 14.03 | 39.20 | 2.60 | -- | 0.0712 | 41.73 | 10.69 | 2.69 | -26.17 | 6.85 | -14.75 | 4.56 |
| Tsumura & Co | 164.61bn | 25.20bn | 370.21bn | 4.14k | 14.53 | 1.24 | 9.66 | 2.25 | 331.93 | 331.93 | 2,167.87 | 3,875.47 | 0.3783 | 0.6916 | 2.48 | 39,781,050.00 | 6.23 | 4.81 | 7.63 | 5.89 | 48.76 | 50.98 | 16.48 | 12.65 | 3.04 | -- | 0.1806 | 32.16 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
| China Medical System Holdings Ltd | 149.61bn | 29.65bn | 370.56bn | 5.78k | 12.51 | 1.08 | 10.78 | 2.48 | 0.6113 | 0.6113 | 3.08 | 7.08 | 0.384 | 2.89 | 5.65 | 1,321,635.00 | 7.51 | 18.44 | 8.53 | 21.14 | 74.13 | 75.47 | 19.56 | 34.26 | 3.97 | -- | 0.0667 | 40.14 | -12.43 | 8.08 | -26.33 | 5.35 | 38.69 | 5.19 |
| Alembic Pharmaceuticals Ltd | 116.26bn | 11.83bn | 373.08bn | 14.86k | 31.56 | 4.17 | 22.06 | 3.21 | 32.88 | 32.88 | 323.14 | 248.68 | 0.929 | 0.9366 | 5.43 | 4,278,678.00 | 9.45 | 10.72 | 13.32 | 14.25 | 73.84 | 65.98 | 10.17 | 12.47 | 0.8057 | 12.62 | 0.1791 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Concord Biotech Ltd | 19.86bn | 6.00bn | 380.96bn | 1.38k | 53.76 | 13.10 | 54.58 | 19.19 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Bora Pharmaceuticals Co Ltd | 79.29bn | 18.51bn | 381.40bn | 91.00 | 20.91 | 6.68 | 16.48 | 4.81 | 37.31 | 37.31 | 158.18 | 116.69 | 0.4986 | 2.37 | 2.37 | -- | 11.92 | 11.27 | 19.26 | 18.66 | 45.08 | 39.25 | 23.91 | 18.55 | 1.40 | 5.93 | 0.5736 | 37.82 | 35.31 | 59.57 | 117.70 | 46.91 | 128.20 | 64.83 |
| Twist Bioscience Corp | 48.37bn | -32.26bn | 382.13bn | 923.00 | -- | 5.19 | -- | 7.90 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 10.43bn | -3.72bn | 383.72bn | 867.00 | -- | 13.79 | -- | 36.79 | -0.6692 | -0.6692 | 1.86 | 4.92 | 0.1677 | 0.2615 | 4.39 | 563,380.80 | -6.54 | -27.13 | -11.06 | -39.20 | 92.64 | 92.75 | -39.00 | -220.71 | 1.83 | -- | 0.4159 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
Data as of Nov 22 2024. Currency figures normalised to Hisamitsu Pharmaceutical Co Inc's reporting currency: Japanese Yen JPY
12.31%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invesco Asset Management (Japan) Ltd.as of 30 Apr 2024 | 3.21m | 3.77% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.18m | 2.56% |
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 1.37m | 1.61% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.03m | 1.21% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 755.20k | 0.89% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 619.50k | 0.73% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 601.20k | 0.71% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 22 Jul 2024 | 277.90k | 0.33% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 224.41k | 0.26% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 219.80k | 0.26% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
